The domestic SGLT-2 inhibitor outpatient prescription market has grown to 170 billion won. It has more than tripled in the past three years. It has been about 10 years since SGLT-2 inhibitors entered Korea. This year, a major change is expected as a number of "Forxiga" generics leading the market are released and new domestic SGLT-2 inhibitors are also released.

◆ SGLT-2, which has grown considerably, grows evenly

According to UBIST, a pharmaceutical market research institute on the 6th, the total amount of outpatient prescriptions for SGLT-2 inhibitors in Korea last year was 172.3 billion won. This is an increase of 14.8% compared to 150.1 billion won in the previous year.